Danaher Corporation

NYSE DHR

Download Data

Danaher Corporation Cash Per Share 2 year CAGR for the year ending December 31, 2023: 49.95%

Danaher Corporation Cash Per Share 2 year CAGR is 49.95% for the year ending December 31, 2023, a 3,253.52% change year over year. The cash per share represents the amount of cash available to each outstanding share of common stock. It is calculated by dividing the total cash by the weighted average number of shares outstanding. This metric provides insight into the cash position of the company on a per-share basis and can be used to evaluate the company's liquidity and ability to distribute cash to shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Danaher Corporation Cash Per Share for the year ending December 31, 2022 was 8.13, a 131.73% change year over year.
  • Danaher Corporation Cash Per Share for the year ending December 31, 2021 was 3.51, a -58.20% change year over year.
  • Danaher Corporation Cash Per Share for the year ending December 31, 2020 was 8.40, a -69.41% change year over year.
  • Danaher Corporation Cash Per Share for the year ending December 31, 2019 was 27.45, a 2,374.28% change year over year.
NYSE: DHR

Danaher Corporation

CEO Mr. Steven M. Rales
IPO Date Jan. 5, 1979
Location United States
Headquarters 2200 Pennsylvania Avenue, NW, Washington, DC, United States, 20037-1701
Employees 61,000
Sector Healthcare
Industry Diagnostics & research
Description

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Similar companies

A

Agilent Technologies Inc

NA

NA

IDXX

IDEXX Laboratories Inc

NA

NA

WAT

Waters Corporation

NA

NA

CRL

Charles River Laboratories

NA

NA

RVTY

Revvity Inc.

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email